{"id":383295,"date":"2020-11-17T12:33:22","date_gmt":"2020-11-17T17:33:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383295"},"modified":"2020-11-17T12:33:22","modified_gmt":"2020-11-17T17:33:22","slug":"glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/","title":{"rendered":"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)"},"content":{"rendered":"
\n

LOS ANGELES, Nov. 17, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP<\/a> (\u201cGPM\u201d) reminds investors of the upcoming\u00a0December 22, 2020<\/strong> deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (\u201cInnate\u201d or the “Company”) (NASDAQ: IPHA<\/u><\/a>) securities between March 10, 2020 and September 8, 2020<\/strong>, inclusive (the \u201cClass Period\u201d).<\/p>\n

If you suffered a loss on your Innate investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https:\/\/www.glancylaw.com\/cases\/innate-pharma-sa\/<\/a>. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com<\/a> to learn more about your rights.<\/p>\n

On\u00a0October 23, 2018, Innate and AstraZeneca plc (“AstraZeneca”) announced an expansion of a pre-existing collaboration agreement, whereby AstraZeneca acquired 9.8% equity stake in Innate and obtained full oncology rights to monalizumab, a first-in-class humanized anti-NKG2A antibody.\u00a0 As part of this agreement, Innate would receive\u00a0$100 million\u00a0in milestone payments at the start of the first Phase 3 clinical trial for monalizumab.\u00a0<\/p>\n

On\u00a0September 8, 2020, Innate announced that it had amended its collaboration agreement with AstraZeneca. Innate “will now receive a\u00a0$50 million\u00a0payment upon AstraZeneca’s dosing of the first patient in the Phase 3 trial, and a\u00a0$50 million\u00a0payment after the interim analysis demonstrates the combination meets a pre-defined threshold of clinical activity.”\u00a0<\/p>\n

On this news, the Company\u2019s American Depositary Share (“ADS”) price fell\u00a0$1.62\u00a0per share, or 26.6%, to close at\u00a0$4.45\u00a0per ADS on\u00a0September 8, 2020.<\/p>\n

The complaint filed alleges that throughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and\/or lacked a reasonable basis at all relevant times.<\/p>\n

Follow us for updates on LinkedIn<\/a>, Twitter<\/a>, or Facebook<\/a>.<\/p>\n

If you purchased\u00a0or otherwise acquired Innate securities during the Class Period,\u00a0you may move the Court no later than\u00a0December <\/strong>2<\/strong>2<\/strong>, 2020\u00a0<\/strong>to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no\u00a0action and remain an absent member of the Class. If you wish to\u202flearn more\u202fabout this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact\u00a0Charles\u00a0Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to\u00a0shareholders@glancylaw.com<\/a>, or visit our website at\u00a0www.glancylaw.com<\/a>. If you inquire by email please include your mailing address, telephone number and number of shares purchased.\u00a0<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

\n Contacts<\/strong>
\n
Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com<\/a>\u00a0\u00a0
shareholders@glancylaw.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LOS ANGELES, Nov. 17, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (\u201cGPM\u201d) reminds investors of the upcoming\u00a0December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (\u201cInnate\u201d or the “Company”) (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the \u201cClass Period\u201d). If you suffered a loss on your Innate investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https:\/\/www.glancylaw.com\/cases\/innate-pharma-sa\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn … <\/p>\n

Continue reading “Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383295","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGlancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, Nov. 17, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (\u201cGPM\u201d) reminds investors of the upcoming\u00a0December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (\u201cInnate\u201d or the “Company”) (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the \u201cClass Period\u201d). If you suffered a loss on your Innate investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https:\/\/www.glancylaw.com\/cases\/innate-pharma-sa\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn … Continue reading "Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T17:33:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)\",\"datePublished\":\"2020-11-17T17:33:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/\"},\"wordCount\":604,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/\",\"name\":\"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=\",\"datePublished\":\"2020-11-17T17:33:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/","og_locale":"en_US","og_type":"article","og_title":"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) - Market Newsdesk","og_description":"LOS ANGELES, Nov. 17, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (\u201cGPM\u201d) reminds investors of the upcoming\u00a0December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (\u201cInnate\u201d or the “Company”) (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the \u201cClass Period\u201d). If you suffered a loss on your Innate investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https:\/\/www.glancylaw.com\/cases\/innate-pharma-sa\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn … Continue reading \"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T17:33:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)","datePublished":"2020-11-17T17:33:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/"},"wordCount":604,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/","name":"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=","datePublished":"2020-11-17T17:33:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI3NSMzODMwMzM2IzIwMTcyOTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glancy-prongay-murray-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-innate-pharma-sa-ipha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383295"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383295\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}